The purpose of this study is to investigate the prognostic value of the systemic immune inflammation index (SII) by comparing it with postoperative TNM stages and other clinical-pathological data in patients undergoing curative surgery for pancreatic cancer. Pathological and clinical data of 44 patients who were operated for pancreatic cancer between January 2012 and January 2020 were retrospectively analyzed. Neutrophil, platelet and lymphocyte counts taken from preoperative complete blood samples were recorded and SII was calculated. The formula used in the calculation of the index is SII = Platelet x Neutrophil / Lymphocyte count. A comparison of the pathological stage and other clinical pathological findings was made for the two groups, which were formed with a cut-off value of 600 for SII. Twenty (45.4%) of the patients were female and 24 (54.5%) were male. Mean patient age was 65.4 ± 5.3 (21-86). In general, as the pathological stages of the patients increased, SII was also observed to increase creating a statistically significant difference (p <0.001). The cut-off value for SII was taken as 600, forming two different groups. The difference in pathological stage distribution of these two groups was found to be statistically significant (p <0.001). The difference between the groups according to differentiation degree, CA 19-9 level, presence of pancreatitis, pT, tumor diameter was statistically significant (respectively p = 0.026, p = 0.009, p = 0.046, p = 0.047, p = 0.017). It shows that preoperative SII significantly correlates with well-established prognostic factors in pancreatic cancer patients undergoing pancreatic surgery (resection). SII measurement is both low cost and easily applicable. SII can be used in conjunction with and supporting wellestablished prognostic factors.